| Unique ID issued by UMIN | UMIN000057136 |
|---|---|
| Receipt number | R000065308 |
| Scientific Title | Pathophysiological analysis of small intestinal bacterial overgrowth (SIBO) |
| Date of disclosure of the study information | 2025/02/26 |
| Last modified on | 2025/02/26 11:13:47 |
Pathophysiological analysis of small intestinal bacterial overgrowth (SIBO)
Pathophysiology of small intestinal bacterial overgrowth (SIBO)
Pathophysiological analysis of small intestinal bacterial overgrowth (SIBO)
pathophysiology of small intestinal bacterial overgrowth (SIBO)
| Japan |
Small intestinal bacterial overgrowth (SIBO)
| Gastroenterology |
Others
NO
Perform breath tests on patients with clinically suspected SIBO to clarify its pathophysiology in Japanese.
Others
Creation of evidence for Japanese SIBO.
Positive diagnostic rate of breath test as the gold standard for SIBO diagnosis by bacterial count.
Sensitivity, specificity, positive predictive value, and negative predictive value of breath test.
Observational
| 18 | years-old | <= |
| 90 | years-old | >= |
Male and Female
Patients suspected of having SIBO
(1) Patients with abdominal symptoms such as abdominal distention and abdominal pain.
(2) Patients with abnormal gas in the small intestine on plain abdominal X-ray or CT scan performed for medical reasons.
(3) No evidence of organic disease (tumor, acute ulcerative lesion, severe stenosis or obstruction, etc.) on abdominal ultrasonography or upper gastrointestinal endoscopy performed for medical necessity.
(4) No antimicrobial agents have been administered for 3 months prior to obtaining consent to participate in this study.
(5) Age between 18 and 90 years old.
(6) Consent for participation in this study is obtained from the patient by signing a consent form.
(1) Patients with a history of surgical operation for gastrointestinal diseases except for cholecystectomy, appendectomy, and hemorrhoidectomy.
(2) Patients who have taken intestinal antiflatulents or intestinal peristaltic drugs within 1 month.
(3) Those who have taken antibiotics within 3 months.
(4) Diabetic patients with poor glycemic control (HbA1c >= 7.0%).
(5) Patients taking alpha-glucosidase inhibitors.
(6) Pregnant or possibly pregnant.
(7) Patients with organic diseases (tumor, acute ulcerative lesion, severe stenosis or obstruction, etc.).
(8) Other patients who are deemed inappropriate by the principal investigator and the study administrator.
200
| 1st name | Takayoshi |
| Middle name | |
| Last name | Suzuki |
Tokai University Hachioji Hospital
Department of gastroenterology
192-0032
1838 Ishikawa machi, Hachioji, Tokyo
042-639-1111
takayosh@tokai.ac.jp
| 1st name | Takayoshi |
| Middle name | |
| Last name | Suzuki |
Tokai University Hachioji Hospital
Department of gastroenterology
192-0032
1838 Ishikawa machi, Hachioji, Tokyo
042-639-1111
takayosh@tokai.ac.jp
Tokai University
Tokai University
Self funding
Research ethics committee, Tokai University school of medicine
143 Shimokasuya, Isehara, Kanagawa
0463-93-1121
tokai-rec@tokai.ac.jp
NO
| 2025 | Year | 02 | Month | 26 | Day |
Unpublished
Preinitiation
| 2024 | Year | 09 | Month | 09 | Day |
| 2025 | Year | 02 | Month | 26 | Day |
| 2027 | Year | 03 | Month | 31 | Day |
The study subjects are patients who visited the Department of Gastroenterology at Hachioji Hospital have abdominal symptoms, and are suspected of having SIBO.
| 2025 | Year | 02 | Month | 26 | Day |
| 2025 | Year | 02 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065308